RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab

NCT01943786 · clinicaltrials.gov ↗

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: FOLFIRI + Cetuximab

Sponsor

Sofia Perea, Director Clinical Trials Unit.